

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-21. (Cancelled)

22. (Currently Amended) A recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1, a Fel d 1 chain 2, wherein the Fel d 1 chain 1 comprises the amino acid sequence set forth in SEQ ID NO: 1 or a variant thereof, wherein Fel d 1 chain 2 comprises (i) the amino acid sequence set forth in SEQ ID NO: 2 or a variant thereof or (ii) the amino acid sequence set forth in SEQ ID NO: 3, wherein the N-terminus of the Fel d 1 chain 1 is in peptide linkage with the C-terminus of the Fel d 1 chain 2, wherein the variant of the amino acid sequence set forth in SEQ ID NO:1 is selected from the group consisting of Lys29Arg, Lys 29Asn and Val33Ser, and wherein the variant of the amino acid sequence set forth in SEQ ID NO:2 is selected from the group consisting of Asn19Ser, Gly20 Leu, ile55Val, Arg57Lys, Val58Phe, Glu69Val, Tyr72Asp, Gln79Glu and Asn88Lys,
and a linker consisting of ~~selected from a carbon-nitrogen bond or a peptide linker~~
consisting of 1 to 9 amino acid residues which links the N terminal amino acid of one chain to the C-terminal amino acid of the other chain.

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Previously presented) A fusion product as claimed in claim 22, wherein the chain 1 and the chain 2 are covalently bonded together by one or more disulfide bridges into an antiparallel arrangement.

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Previously presented) A homodimer consisting of two non-covalently associated fusion products as claimed in claim 22.

34. (Withdrawn) A DNA sequence encoding the fusion product as claimed in claim 22.

35. (Withdrawn) An expression vector having the DNA sequence as claimed in claim 34 inserted therein in an operable form.

36. (Withdrawn) A host cell transformed with the expression vector as claimed in claim 35.

37. (Previously presented) A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 22

and/or the homodimer as claimed in claim 33 and a pharmaceutically acceptable carrier, excipient or diluent.

38. (Previously presented) A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and instructions for use of the kit.

39. (Withdrawn) A method for diagnosing cat allergy comprising the step of combining a sample taken from a subject with the fusion product as claimed in claim 22, the homodimer as claimed in claim 33, or a combination thereof.

40. (Withdrawn) A process for preparing a fusion product as claimed in claim 22 comprising the step of culturing the host cell as claimed in claim 36 in a suitable medium.

41. (Canceled)

42. (New) The fusion product of claim 22, wherein the Fel d 1 chain 2 further has a methionine residue on the N-terminus.

43. (New) The fusion product of claim 22, wherein the Fel d 1 chain 1 further has the sequence Leu-Glu-(His)₆ on the C-terminus.

44. (New) The fusion product of claim 42, wherein the Fel d 1 chain 1 further has the sequence Leu-Glu-(His)₆ on the C-terminus.

45. (New) The fusion product of claim 44, wherein the fusion product has the amino acid sequence set forth in SEQ ID NO: 4.

46. (New) A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 45 and a pharmaceutically acceptable carrier, excipient or diluent.

47. (New) A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 45 and instructions for use of the kit.